Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company

Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site

Fineline Cube Mar 20, 2024

Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...

Company

Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...

Company

WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production

Fineline Cube Mar 20, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation

Fineline Cube Mar 20, 2024

Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has...

Company Drug

Everest Medicines’ Nefegan Approved by Singapore HSA for Primary IgAN Treatment

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a China-based biotechnology company, has received marketing approval from the Singapore...

Company

Shanghai Pharmaceuticals Appoints New Chairman Amid Leadership Shake-up

Fineline Cube Mar 20, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), one of the leading pharmaceutical giants in China,...

Company Deals

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

Fineline Cube Mar 20, 2024

AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...

Company

China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements

Fineline Cube Mar 20, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...

Company Drug

Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin

Fineline Cube Mar 20, 2024

Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...

Company Drug

Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial

Fineline Cube Mar 20, 2024

Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled...

Company Drug

China Medical System Gets Green Light for Phase III Clinical Trial of Opzelura in Atopic Dermatitis

Fineline Cube Mar 20, 2024

China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...

Company Drug

AstraZeneca’s Lynparza-Imfinzi Combo Shows Promising Results in Endometrial Cancer Study

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has presented interim results from a late-stage...

Policy / Regulatory

China’s National Joint Procurement Office Sets March 2024 for Insulin Contracts Renewal

Fineline Cube Mar 19, 2024

The National Joint Procurement Office in China has released a notification outlining the information and...

Company

WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles

Fineline Cube Mar 19, 2024

WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results...

Company Drug

Teruisi Pharma’s TRS005 Receives Support for Breakthrough Designation in China for CD20-Positive Lymphoma

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE) in China has signaled that Teruisi Pharma’s antibody drug...

Company Drug

Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...

Policy / Regulatory

CDE Seeks Public Feedback on Latest Batch of Generic Drug Reference Preparations

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE), a key regulatory body overseeing pharmaceutical evaluations in China,...

Company Drug

AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its...

Company Drug

Jiangsu Yahong Meditech to Present Phase III Results for Cervical Cancer Treatment at SGO Annual Meeting

Fineline Cube Mar 19, 2024

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, is...

Company Medical Device

Sino Medical Sciences Secures South Korean Approvals for Three Cardiovascular Devices

Fineline Cube Mar 19, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Posts pagination

1 … 343 344 345 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.